Seeking Alpha

The sell-off in Optimer Pharmaceuticals (OPTR -16.6%) accelerates as the session drags on, with...

The sell-off in Optimer Pharmaceuticals (OPTR -16.6%) accelerates as the session drags on, with losses now well into the double-digits. On top of Needham's downgrade (disappointing Dificid sales may equate to less value for anyone planning an acquisition), Baird chimes in as well, cutting the shares to Neutral from Outperform (price target still $16). (earnings, CC)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs